Research ArticleAccepted Article
Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase-Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase-2 Study
Mark Genovese, Alberto Spindler, Akira Sagawa, Won Park, Anna Dudek, Alan Kivitz, Jeannie Chao, Melanie Lai Shan Chan, Jennifer Witcher, William Barchuk and Ajay Nirula
The Journal of Rheumatology December 2020, jrheum.200893; DOI: https://doi.org/10.3899/jrheum.200893
Mark Genovese
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Alberto Spindler
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Akira Sagawa
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Won Park
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Anna Dudek
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Alan Kivitz
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Jeannie Chao
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Melanie Lai Shan Chan
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Jennifer Witcher
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
William Barchuk
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Ajay Nirula
Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA; Centro Medico Privado de Reumatologia, Tucumán, Argentina; Sagawa Akira Rheumatology Clinic, Sapporo, Japan; Division of Rheumatology, IN-HA University, Incheon, Korea; AMED Medical Center, Warsaw, Poland; Altoona Center for Clinical Research, Duncansville, PA, USA; Eli Lilly and Company, Indianapolis, IN, USA. Address correspondence to: Mark C. Genovese, James W. Raitt Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. E-mail: genovese@stanford.edu
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Accepted manuscript
Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase-Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase-2 Study
Mark Genovese, Alberto Spindler, Akira Sagawa, Won Park, Anna Dudek, Alan Kivitz, Jeannie Chao, Melanie Lai Shan Chan, Jennifer Witcher, William Barchuk, Ajay Nirula
The Journal of Rheumatology Dec 2020, jrheum.200893; DOI: 10.3899/jrheum.200893
Accepted manuscript
Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase-Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase-2 Study
Mark Genovese, Alberto Spindler, Akira Sagawa, Won Park, Anna Dudek, Alan Kivitz, Jeannie Chao, Melanie Lai Shan Chan, Jennifer Witcher, William Barchuk, Ajay Nirula
The Journal of Rheumatology Dec 2020, jrheum.200893; DOI: 10.3899/jrheum.200893